NO20085121L - Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme - Google Patents
Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende sammeInfo
- Publication number
- NO20085121L NO20085121L NO20085121A NO20085121A NO20085121L NO 20085121 L NO20085121 L NO 20085121L NO 20085121 A NO20085121 A NO 20085121A NO 20085121 A NO20085121 A NO 20085121A NO 20085121 L NO20085121 L NO 20085121L
- Authority
- NO
- Norway
- Prior art keywords
- mate
- preparation
- benzimidazole derivatives
- pharmaceutical compositions
- same
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title abstract 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06116302 | 2006-06-29 | ||
PCT/EP2007/055994 WO2008000643A1 (en) | 2006-06-29 | 2007-06-18 | Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20085121L true NO20085121L (no) | 2009-01-27 |
Family
ID=38462503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20085121A NO20085121L (no) | 2006-06-29 | 2008-12-09 | Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme |
Country Status (17)
Country | Link |
---|---|
US (1) | US7645785B2 (ru) |
EP (1) | EP2038259A1 (ru) |
JP (1) | JP4970538B2 (ru) |
KR (1) | KR101237623B1 (ru) |
CN (1) | CN101479249B (ru) |
AR (1) | AR061666A1 (ru) |
AU (1) | AU2007263807B2 (ru) |
BR (1) | BRPI0713946A2 (ru) |
CA (1) | CA2655395C (ru) |
CL (1) | CL2007001869A1 (ru) |
IL (1) | IL195748A0 (ru) |
MX (1) | MX2008015923A (ru) |
NO (1) | NO20085121L (ru) |
RU (1) | RU2424233C2 (ru) |
TW (1) | TWI329638B (ru) |
WO (1) | WO2008000643A1 (ru) |
ZA (1) | ZA200810481B (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200736227A (en) * | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2697167C (en) * | 2007-08-27 | 2013-07-16 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives used as fxr agonists |
JP5222953B2 (ja) * | 2007-11-15 | 2013-06-26 | エフ.ホフマン−ラ ロシュ アーゲー | ベンゾイミダゾール誘導体及びfxrアゴニストとしてのその使用 |
US7816540B2 (en) | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
AU2009291001A1 (en) | 2008-09-11 | 2010-03-18 | F. Hoffmann-La Roche Ag | New benzimidazole derivatives |
AU2009304169A1 (en) | 2008-10-15 | 2010-04-22 | F. Hoffmann-La Roche Ag | New benzimidazole derivatives |
US8309581B2 (en) * | 2009-09-29 | 2012-11-13 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
EP2501696B1 (en) * | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8252826B2 (en) * | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
CA2891348C (en) * | 2012-11-28 | 2020-04-28 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
US9828345B2 (en) | 2013-02-28 | 2017-11-28 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
LT3043865T (lt) | 2013-09-11 | 2021-04-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Hepatito b viruso infekcijos gydymo būdai ir farmacinė kompozicija |
MX2017005158A (es) * | 2014-10-28 | 2017-07-27 | Shionogi & Co | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). |
WO2017168451A1 (en) * | 2016-03-31 | 2017-10-05 | Shiv Nadar University | Derivatives of imidazole and benzimidazole, method of preparation and use thereof |
JP6903732B2 (ja) | 2016-07-14 | 2021-07-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Par4阻害剤としての三環式ヘテロアリール置換のキノリンおよびアザキノリン化合物 |
JP6990228B2 (ja) | 2016-07-14 | 2022-01-13 | ブリストル-マイヤーズ スクイブ カンパニー | 二環式ヘテロアリール置換の化合物 |
CN109790162B (zh) * | 2016-07-27 | 2022-06-28 | 帕德罗科治疗公司 | Pad4的共价抑制剂 |
WO2018051229A1 (en) * | 2016-09-14 | 2018-03-22 | Novartis Ag | Novel regimes of fxr agonists |
CN106905241B (zh) * | 2017-02-14 | 2020-03-17 | 沈阳药科大学 | 1,2-二取代苯并咪唑衍生物及其应用 |
KR20190117632A (ko) | 2017-02-21 | 2019-10-16 | 장피트 | Ppar 효현제와 fxr 효현제의 병용 |
CN110944635A (zh) | 2017-03-30 | 2020-03-31 | 国家医疗保健研究所 | 用于减少附加体病毒的持久性和表达的方法和药物组合物 |
KR102648947B1 (ko) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
CN111574442A (zh) * | 2017-12-29 | 2020-08-25 | 杭州阿诺生物医药科技有限公司 | 吲哚胺2,3-双加氧酶抑制剂的制备方法 |
WO2019129114A1 (zh) * | 2017-12-29 | 2019-07-04 | 杭州阿诺生物医药科技有限公司 | 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 |
CN111072604B (zh) * | 2018-10-18 | 2022-11-04 | 广东东阳光药业有限公司 | α-氨基酰胺衍生物及其用途 |
KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
CN112409281B (zh) * | 2020-08-20 | 2022-11-18 | 上海大学 | (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
WO2001021634A1 (en) * | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
US6855714B2 (en) * | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Gsk-3의 억제제로서 유용한 헤테로아릴 화합물 |
WO2003080803A2 (en) * | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
-
2007
- 2007-06-18 CN CN2007800235626A patent/CN101479249B/zh not_active Expired - Fee Related
- 2007-06-18 JP JP2009517105A patent/JP4970538B2/ja not_active Expired - Fee Related
- 2007-06-18 EP EP07765461A patent/EP2038259A1/en not_active Withdrawn
- 2007-06-18 CA CA2655395A patent/CA2655395C/en not_active Expired - Fee Related
- 2007-06-18 WO PCT/EP2007/055994 patent/WO2008000643A1/en active Search and Examination
- 2007-06-18 MX MX2008015923A patent/MX2008015923A/es active IP Right Grant
- 2007-06-18 RU RU2009102770/04A patent/RU2424233C2/ru not_active IP Right Cessation
- 2007-06-18 BR BRPI0713946-2A patent/BRPI0713946A2/pt not_active IP Right Cessation
- 2007-06-18 AU AU2007263807A patent/AU2007263807B2/en not_active Ceased
- 2007-06-18 KR KR1020087031557A patent/KR101237623B1/ko not_active IP Right Cessation
- 2007-06-22 US US11/821,265 patent/US7645785B2/en not_active Expired - Fee Related
- 2007-06-26 TW TW096122983A patent/TWI329638B/zh not_active IP Right Cessation
- 2007-06-26 CL CL200701869A patent/CL2007001869A1/es unknown
- 2007-06-27 AR ARP070102858A patent/AR061666A1/es not_active Application Discontinuation
-
2008
- 2008-12-04 IL IL195748A patent/IL195748A0/en unknown
- 2008-12-09 NO NO20085121A patent/NO20085121L/no not_active Application Discontinuation
- 2008-12-10 ZA ZA200810481A patent/ZA200810481B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007263807A1 (en) | 2008-01-03 |
KR101237623B1 (ko) | 2013-02-26 |
MX2008015923A (es) | 2009-01-13 |
CN101479249A (zh) | 2009-07-08 |
TWI329638B (en) | 2010-09-01 |
TW200811112A (en) | 2008-03-01 |
RU2009102770A (ru) | 2010-08-10 |
BRPI0713946A2 (pt) | 2012-12-04 |
EP2038259A1 (en) | 2009-03-25 |
IL195748A0 (en) | 2009-09-01 |
AR061666A1 (es) | 2008-09-10 |
RU2424233C2 (ru) | 2011-07-20 |
CL2007001869A1 (es) | 2008-02-08 |
CA2655395C (en) | 2011-10-11 |
WO2008000643A1 (en) | 2008-01-03 |
US7645785B2 (en) | 2010-01-12 |
US20080021027A1 (en) | 2008-01-24 |
JP2009541413A (ja) | 2009-11-26 |
KR20090016605A (ko) | 2009-02-16 |
CN101479249B (zh) | 2012-10-10 |
AU2007263807B2 (en) | 2011-06-02 |
ZA200810481B (en) | 2009-12-30 |
JP4970538B2 (ja) | 2012-07-11 |
CA2655395A1 (en) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20085121L (no) | Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme | |
NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
NO20091548L (no) | Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes | |
MX2010006565A (es) | Derivados de benzimidazol sustituido por carboxilo o hidroxilo. | |
EA201070698A1 (ru) | Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
NO20071593L (no) | Pyrimidinderivater | |
HK1138840A1 (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
NO20084923L (no) | N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer | |
NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
WO2008145688A3 (en) | Pyrrolopyridine compounds, process for their preparation, and their use as medicaments | |
NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
NO20090628L (no) | Pyridizinon derivativater | |
NO20076648L (no) | Novel thiophene derivatives | |
NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
MX2010002341A (es) | Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. | |
MX2010005824A (es) | Derivados de aminotiazol. | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
NO20084363L (no) | 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister | |
NO20085212L (no) | Nye pyridinanaloger | |
DK2368887T3 (da) | 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |